Literature DB >> 2984321

Enhancing antibodies, macrophages and virulence in mouse cytomegalovirus infection.

T Inada, K T Chong, C A Mims.   

Abstract

The infectivity of tissue culture-passed mouse cytomegalovirus (MCMV) for resident mouse peritoneal macrophages in the presence of serial dilutions of antiviral antibody was studied by fluorescent antibody staining and virus yields. Although MCMV was neutralized by high concentrations of antiserum, there was a twofold enhancement of infectivity by subneutralizing antibody concentrations. On further dilution of antiserum, significant neutralization appeared again. When F(ab')2 fragments of anti-MCMV IgG were used or when macrophages were pretreated with monoclonal antibody to Fc receptor, there was no enhancement, and no neutralization at high dilutions of antiserum. This suggests that both enhancement and high dilution neutralization are mediated via the Fc portion of IgG and Fc receptors of macrophages. Tissue culture-passed virus whose infectivity for macrophages was reduced by high dilutions of antibody was converted to a more infectious state by addition of anti-mouse immunoglobulin. Similar results were obtained with salivary gland virus, which is less infectious for macrophages and is coated with non-neutralizing antibody. Tissue culture-passed virus is known to be less virulent for suckling mice and more infectious for macrophages than salivary gland-passed virus. When tissue culture-passed virus was coated with appropriately diluted antiviral antibody, not only was its infectivity for macrophages reduced, but it also became more virulent than control virus treated with normal mouse serum. These results are interpreted in terms of the optimal density of Fc on the virus-immunoglobulin complex in relation to the density of Fc receptors on macrophages.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984321     DOI: 10.1099/0022-1317-66-4-871

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  15 in total

Review 1.  Animal cytomegaloviruses.

Authors:  J Staczek
Journal:  Microbiol Rev       Date:  1990-09

2.  DMSO induces reactivation of cytomegalovirus in vitro from spleens of latently infected mice. Brief report.

Authors:  S Blackett; A Gupta; C A Mims
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

Review 3.  Interactions of viruses with the immune system.

Authors:  C A Mims
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

4.  Attenuated murine cytomegalovirus binds to N-acetylglucosamine, and shift to virulence may involve recognition of sialic acids.

Authors:  R M Ravindranath; M C Graves
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

5.  Replication of murine cytomegalovirus in mast cells.

Authors:  A E Gibbons; P Price; T A Robertson; J M Papadimitriou; G R Shellam
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

6.  Glycoprotein L sets the neutralization profile of murid herpesvirus 4.

Authors:  Laurent Gillet; Marta Alenquer; Daniel L Glauser; Susanna Colaco; Janet S May; Philip G Stevenson
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

7.  Antibody dependent enhancement of frog virus 3 infection.

Authors:  Heather E Eaton; Emily Penny; Craig R Brunetti
Journal:  Virol J       Date:  2010-02-18       Impact factor: 4.099

8.  Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus.

Authors:  W V Corapi; C W Olsen; F W Scott
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

9.  Interaction of poliovirus with its receptor affords a high level of infectivity to the virion in poliovirus infections mediated by the Fc receptor.

Authors:  M Arita; H Horie; M Arita; A Nomoto
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Transplacental murine cytomegalovirus infection in the brain of SCID mice.

Authors:  Nigel K Woolf; Dawn V Jaquish; Fred J Koehrn
Journal:  Virol J       Date:  2007-03-09       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.